Global Cell and Gene Therapy Market - Estimated 2021, Projected 2026 and 2031 - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Cell and Gene Therapy World Market and Market Potential" report has been added to ResearchAndMarkets.com's offering.

The report examines developments in cell and gene therapy markets by condition/disorder, including principal products, trends in research and development, market breakdown of cell and gene therapies, regional market summary, and competitor summary.

Companies Mentioned

• Advaxis, Inc. (Biosight Therapeutics)
• Allosource
• Alnylam Pharmaceuticals, Inc.
• Amgen
• Anges Inc.
• Anterogen Co Ltd.
• Atara Biotherapeutics
• Athersys, Inc
• Biocardia
• Biogen, Inc.
• Biomarin Pharmaceuticals
• Bluebird Bio, Inc.
• Brainstorm Cell Therapeutics
• Bristol-Myers Squibb
• Caladrius Biosciences
• Candel Therapeutics
• Castle Creek Biosciences
• Celyad Oncology
• Cook Myosite, Inc
• Cytori Therapeutics, Inc
• Dendreon Pharmaceuticals LLC
• Fergene, Inc/Ferring Pharmaceuticals
• Gamida Cell Ltd.
• Gensight Biologics S.A.
• Gilead Sciences, Inc.
• And Many More Companies!

The following conditions/disorders are covered:

Dermatology, including:

• Dermatology Cell and Gene Therapy Markets by Product Type, Estimated 2021 and Projected 2026 and 2031 ($ millions) (Stem cells, Skin cells)
• Dermatology Cell and Gene Therapy Market by General Indication, Estimated 2021, Projected 2026 and 2031 ($ millions) (Wound healing/treatment, Other indications [wrinkles, scar treatment])
• Dermatology Cell and Gene Therapy Market by Country/Region, Estimated 2021, Projected 2026 and 2031 ($ millions) (United States, Europe/European Union, S. Korea, Other countries)
• Dermatology Cell and Gene Therapy Competitor Market Share, Reported and Estimated 2021 ($ millions)

Cardiovascular and Blood Disorders, including:

• Cardiovascular and Blood Disorders Cell and Gene Therapy Markets by Product Type, Estimated 2021 and Projected 2026 and 2031 ($ millions) (Stem cells, Gene therapy, Other cell therapies; Stromal cells)
• Cardiovascular and Blood Disorders Cell and Gene Therapy Market by General Indication, Estimated 2021, Projected 2026 and 2031 ($ millions) (Cardiac disorders, Vascular disorders, Blood disorders, Hypercholesterolemia)
• Cardiovascular and Blood Disorders Cell and Gene Therapy Market Summary by Geographic Region, Estimated 2021 and Projected 2026, 2030 ($ millions) (United States, Europe, S. Korea, Japan, ROW)

Oncology, including:

• Oncology Cell and Gene Therapy Markets by Product Type, Estimated 2021 and Projected 2026 and 2031 ($ millions) (CAR-T, Cell immunotherapy, Gene therapy, Other cell therapy)
• Oncology Cell and Gene Therapy Market by General Indication, Estimated 2021, Projected 2026 and 2031 ($ millions) (Blood cancers, Prostate cancer, Melanoma, Other cancers)
• Oncology Cell and Gene Therapy Market Summary by Geographic Region, Estimated 2021 and Projected 2026, 2030 ($ millions) (United States, Europe, ROW)
• Oncology Cell and Gene Therapy Competitor Market Share, Reported and Estimated 2021 ($ millions)

Ophthalmic Conditions, including:

• Ophthalmology Cell and Gene Therapy Markets by Product Type, Estimated 2021 and Projected 2026 and 2031 ($ millions) (Stem cells, Gene therapy, Other cell therapy)
• Ophthalmology Cell and Gene Therapy Market Summary by Geographic Region, Estimated 2021 and Projected 2026, 2030 ($ millions) (United States, Europe, Other countries)

Musculoskeletal Conditions and Disorders, including:

• Musculoskeletal Cell Therapy Market, Estimated 2021 and Projected 2026 and 2031 ($ millions)
• Musculoskeletal Cell and Gene Therapy Market by General Indication, Estimated 2021, Projected 2026 and 2031 ($ millions) (Cartilage Defect/Damage Repair, Bone Defect/Damage Repair, Others [tendon damage, osteoarthritis])
• Musculoskeletal Cell and Gene Therapy Market by Country/Region, Estimated 2021, Projected 2026 and 2031 ($ millions) (United States, Europe/European Union, S. Korea, Other countries)
• Musculoskeletal Cell Therapy Competitor Market Share, Reported and Estimated 2021 ($ millions)

Other Conditions, including:

• Other Conditions Cell and Gene Therapy Markets by Product Type, Estimated 2021 and Projected 2026 and 2031 ($ millions) (Cell therapy, Gene therapy, Gene-modified cell therapy)
• Other Conditions Cell and Gene Therapy Market by Country/Region, Estimated 2021, Projected 2026 and 2031 ($ millions) (United States, Europe/European Union, S. Korea, Other countries)

Key Topics Covered:

CHAPTER 1: EXECUTIVE SUMMARY

CHAPTER 2: INTRODUCTION TO CELL AND GENE THERAPY

CHAPTER 3: CELL AND GENE THERAPY MARKETS IN DERMATOLOGY OVERVIEW

CHAPTER 4: CELL AND GENE THERAPY MARKETS IN CARDIOVASCULAR AND BLOOD DISORDERS

CHAPTER 5: CELL AND GENE THERAPY MARKETS IN ONCOLOGY

CHAPTER 6: CELL AND GENE THERAPY MARKETS IN OPHTHALMIC CONDITIONS

CHAPTER 7: CELL AND GENE THERAPY MARKETS IN MUSCULOSKELETAL CONDITIONS AND DISORDERS

CHAPTER 9: CELL AND GENE THERAPY MARKETS IN OTHER CONDITIONS

CHAPTER 10: CELL AND GENE THERAPY MARKET REVIEW

CHAPTER 11: MARKET PARTICIPANTS

For more information about this report visit https://www.researchandmarkets.com/r/9zzs53